Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Katharina Pomej,1,2,* Lorenz Balcar,1– 3,* Bernhard Scheiner,1– 4 Georg Semmler,1,3 Tobias Meischl,1,2 Mattias Mandorfer,1,3,4 Thomas Reiberger,1,3– 5 Christian Müller,1,2 Michael Trauner,1,4 Matthias Pinter1,2,4 1Division of Gastroenterology and Hepatology, Department of Internal Me...
Guardado en:
Autores principales: | Pomej K, Balcar L, Scheiner B, Semmler G, Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/34e445ecb8884eeb86cb8d444efa3051 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Liming Zheng, et al.
Publicado: (2021) -
Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma
por: Elsayed MMA, et al.
Publicado: (2019) -
Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma
por: Li Z, et al.
Publicado: (2020) -
MiRNA-200b reverses drug resistance of hepatocellular carcinoma HepG2 cells to sorafenib and its underlying mechanism
por: DENG Yong, et al.
Publicado: (2021) -
ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma
por: Wenbin Huang, et al.
Publicado: (2021)